BV
BVS.US Bioventus Inc
- Market cap
- USD 730M
- P/E
- 13.2x
- P/B
- 3.09x
- ROE
- 23.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BVS.US undervalued?
Graham numberBVS.US trades 34.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioventus Inc fundamental analysis
No fundamental analysis for Bioventus Inc yet.
Bioventus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimul…
Full company profileBioventus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bioventus Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 275M | 292M | 319M | 340M | 321M | 431M | 512M | 512M | 573M | 568M | 570M |
| Gross Profit | 183M | 200M | 235M | 249M | 234M | 303M | 331M | 328M | 388M | 382M | 390M |
| Operating Income | 14.9M | 27.0M | 25.5M | 31.2M | 21.2M | 12.1M | -167M | -81.7M | -12.0M | 58.5M | 50.3M |
| EBITDA | 44.0M | 59.8M | 54.5M | 61.6M | 54.3M | 45.5M | -122M | -23.1M | 39.2M | 99.2M | 94.1M |
| Net Income | -18.0M | -1.64M | -12.2M | 6.85M | 16.4M | 19.4M | -159M | -156M | -33.5M | 22.7M | 56.7M |
| EPS | -0.32 | -0.03 | -0.21 | 0.12 | 0.44 | 0.43 | -2.59 | -2.49 | -0.51 | 0.33 | 0.78 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | 443M | 472M | 494M | 1.23B | 1.37B | 811M | 728M | 684M | 673M |
| Total Liabilities | - | - | 297M | 327M | 350M | 692M | 960M | 590M | 542M | 455M | 382M |
| Shareholders' Equity | - | - | 145M | 143M | 142M | 459M | 325M | 174M | 148M | 184M | 240M |
| Cash & Short-term Investments | - | - | 42.8M | 64.5M | 86.8M | 43.9M | 30.2M | 37.0M | 41.6M | 51.2M | 30.7M |
| Total Debt | - | - | 195M | 198M | 188M | 358M | 418M | 395M | 336M | 311M | 244M |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | 45.2M | 40.7M | 71.8M | 23.0M | -13.5M | 15.3M | 38.8M | 74.0M | 66.0M |
| Capital Expenditure | - | - | 6.06M | 8.34M | 20.7M | 7.37M | 1.48M | 7.36M | 1.01M | 2.56M | 2.49M |
| Free Cash Flow | - | - | 39.1M | 32.4M | 51.1M | 15.6M | -15.0M | 7.98M | 37.8M | 71.4M | 63.5M |
| Ratios | |||||||||||
| ROE | - | - | -8.4% | 4.8% | 11.5% | 4.2% | -48.8% | -90.0% | -22.7% | 12.3% | 23.6% |
| ROA | - | - | -2.8% | 1.5% | 3.3% | 1.6% | -11.6% | -19.3% | -4.6% | 3.3% | 8.4% |
| Net Profit Margin | -6.5% | -0.6% | -3.8% | 2.0% | 5.1% | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% | 9.9% |
| Debt to Equity | - | - | 1.34x | 1.38x | 1.32x | 0.78x | 1.29x | 2.27x | 2.27x | 1.69x | 1.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bioventus Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 9.14M | 0.15 | - |
| 2021 | USD 367K | 0.01 | 1.9% |
| 2020 | USD 19.9M | 0.53 | 121.2% |
| 2019 | USD 9.14M | 0.16 | 133.4% |
| 2018 | USD 7.85M | 0.14 | - |
| 2015 | USD 1.02M | 0.02 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bioventus Inc
- Insiders 11.69%
- Institutions 85.99%
- Public & others 2.32%
- Shares outstanding 68.5M
- Free float 34.5M
Top funds holding BVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Avantis US Small Cap Value ETF | 1.92M | 2.80% | +0.82% | Oct 2026 |
| Brown Advisory Small-Cap Fdmtl Val Inv | 1.24M | 1.81% | -0.57% | Sep 2026 |
| iShares Russell 2000 ETF | 1.22M | 1.77% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.16M | 1.70% | 0.00% | Sep 2026 |
| Royce Small-Cap Opportunity Invmt | 817K | 1.19% | -4.86% | Sep 2026 |
| FTGF RY US SmCp Opp A USD Dis(A) | 743K | 1.09% | -10.14% | Sep 2026 |
| Oberweis Micro-Cap | 685K | 1.00% | +13.76% | Jun 2026 |
| Fidelity Small Cap Index | 526K | 0.77% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 447K | 0.65% | -0.38% | Oct 2026 |
| 1832 AM Quantitative Glb Sm Cap EqPoolKM | 343K | 0.50% | 0.00% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 329K | 0.48% | +0.27% | Oct 2026 |
| Principal SmallCap Growth I Instl | 283K | 0.41% | +107.42% | Sep 2026 |
| Vanguard Russell 2000 ETF | 280K | 0.41% | +1.30% | Sep 2026 |
| Lazard Baylight US Sm Cap Eq WW Dist EUR | 250K | 0.36% | +0.61% | Jul 2026 |
| Schwab US Small-Cap ETF™ | 247K | 0.36% | +0.23% | Oct 2026 |
| DFA U.S. Small Cap I | 228K | 0.33% | +0.74% | Sep 2026 |
| DFA US Micro Cap I | 218K | 0.32% | +3.39% | Sep 2026 |
| Fidelity Extended Market Index | 215K | 0.31% | -5.61% | Sep 2026 |
| Dimensional US Small Cap ETF | 214K | 0.31% | 0.00% | Oct 2026 |
| Brown Advisory Small-Cap Growth Inv | 205K | 0.30% | +44.68% | Sep 2026 |
Top institutions holding BVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Essex Woodlands Health Ventures | 13.0M | 19.02% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 12.0M | 17.53% | +96.01% | Jun 2026 |
| Juniper Investment Co, LLC | 6.94M | 10.13% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.44M | 5.02% | +9.65% | Jun 2026 |
| Royce & Associates, LP | 1.83M | 2.68% | +18.94% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.75M | 2.56% | +2.16% | Jun 2026 |
| Geode Capital Management, LLC | 1.37M | 1.99% | +16.90% | Jun 2026 |
| American Century Companies Inc | 1.35M | 1.98% | +118.36% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.24M | 1.81% | +9.58% | Sep 2026 |
| State Street Corp | 1.10M | 1.61% | +11.79% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.04M | 1.52% | +7.17% | Jun 2026 |
| Hillsdale Investment Management Inc. | 908K | 1.33% | +35.25% | Jun 2026 |
| Engine Capital Management LP | 901K | 1.32% | +185.88% | Jun 2026 |
| Wellington Management Company LLP | 748K | 1.09% | +385.50% | Jun 2026 |
| Renaissance Technologies Corp | 736K | 1.07% | +50.37% | Jun 2026 |
| Oberweis Asset Management Inc | 710K | 1.04% | +12.99% | Jun 2026 |
| The Goldman Sachs Group Inc | 652K | 0.95% | +37.81% | Jun 2026 |
| Kennedy Capital Management Inc | 467K | 0.68% | -1.77% | Jun 2026 |
| FMR Inc | 453K | 0.66% | +14.29% | Jun 2026 |
| Northern Trust Corp | 444K | 0.65% | +22.33% | Jun 2026 |
Bioventus Inc company profile
- Company name
- Bioventus Inc
- Ticker
- BVS.US
- Exchange
- USA Stocks
- Listed since
- Feb 11, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 960
- Fiscal year end
- December
- Address
- 4721 Emperor Boulevard, Durham, NC, United States, 27703
- Phone
- 919 474 6700
- Website
- bioventus.com
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc management
8- Mr. Robert E. ClaypoolePresident, CEO & Director · born 1972
- Mr. Mark L. SingletonSenior VP & CFO · born 1969
- Mr. Anthony D'Adamio J.D.Senior VP, General Counsel & Corporate Secretary · born 1961
- Mr. Mike Crowe B.S., M.B.A.Senior Vice President of Operations
- Mr. David CrawfordVice President of Investor Relations & Treasurer
- Ms. Katrina J. Church J.D.Senior VP & Chief Compliance Officer · born 1962
- Ms. Helen LeupoldSenior VP & Chief Human Resources Officer
- Mr. Dave VennerSenior VP & GM of Surgical